Skip to content
PreclinicalResearch compound

Gestrinone (Dimetrose, Nemestran)

Steroid for endometriosis that is also sold as a muscle builder; this effect is not proven in humans, banned on the anti-doping list.

Gestrinone (Dimetrose, Nemestran) vial

DETAILED OVERVIEW

What is Gestrinone (Dimetrose, Nemestran)?

Gestrinone (Dimetrose, Nemestran) is a synthetic steroid that the French company Roussel-Uclaf developed to treat endometriosis, meaning womb-lining tissue growing outside the womb, and it was introduced in Europe in 1986. Today it is a prescription medicine in only a few countries, such as Italy and Brazil, and it was never approved in the United States. For a short time it was also sold on the black market as a muscle-building agent among bodybuilders. It is banned year-round on the anti-doping list.

It acts on several hormone receptors at once, including weakly as a male hormone. Its muscle-building effect has mainly been studied in animals, where it proved weak, and it has not been shown in humans. Side effects include acne, hair growth, a drop in HDL cholesterol and raised liver enzymes; in women it can cause irreversible voice deepening and an enlarged clitoris. It must not be used in pregnancy or while breastfeeding, because it can harm the unborn baby's sexual development.

Mechanism

Mixed PR agonist-antagonist + weak AR + weak ER antagonist + GnRH suppression

Anabolic:Androgenic

Weak (low in classical rat bioassay, ~10-20% of Test)

Half-life

~24 h (oral)

Onset

2-4 weeks (endometriosis Rx symptomatic improvement 4-6 weeks)

Legal status

Endometriosis Rx in Europe (Dimetrose) historically; withdrawn in several countries today. WADA-banned S1.1.a.

Data console

Lab data

Androgenic:AnabolicWeak – classical rat-ventral-prostate + levator-ani bioassay shows ~10-20% Test-level androgenic activity (UGL marketing claims of 'strong anabolic' lack clinical precedent).
AR bindingMixed multi-receptor: PR weak-moderate…
Active half-life~24 h
Detection windowUrinary: 7-14 days (gestrinone metabolites by LC-MS/MS, WADA-accredited).
AromatizationNO – Gestrinone is NOT a CYP19 substrate (the 4,9,11-triene system blocks aromatase conversion). Therefore in bodybuilding context it is sometimes cited as having an 'anti-estrogen effect', BUT the weak ER antagonism has little clinical significance outside high doses (Tamaya 1986 PMID 3719842).
HepatotoxicityModerate – 17α-ethynyl substitution slows CYP3A4-mediated metabolism similarly to 17α-alkylated AAS, ALT/AST 1.5-3x elevation at therapeutic dose (Fedele 1989 PMID 2660361). Not as hepatotoxic as classical 17α-methyl AAS (e.g. Anadrol), but NOT a 'clean' lipid/hepatic profile.

Safety

Side effects, stop signs, contraindications

Side effects · 8

  • Androgenic side effects: acne, oily skin and hirsutism (excess hair growth), the most common adverse effects reported in clinical endometriosis trials.
  • Virilization in women: irreversible voice deepening and clitoral enlargement can occur, especially with prolonged or higher-dose use.
  • Adverse lipid profile: reduction in HDL (good cholesterol), a hallmark of 17alpha-ethynyl steroids that raises cardiovascular risk.
  • Liver enzyme elevation: ALT/AST can rise moderately (roughly 1.5-3x) even at therapeutic doses, due to the slowed hepatic metabolism from the 17alpha-ethynyl substitution.
  • Amenorrhoea and menstrual disturbances: hypothalamic suppression and endometrial atrophy thin or stop menstruation; breakthrough spotting can also occur.
  • Gastrointestinal symptoms: nausea and abdominal discomfort occur in about 20% of patients in clinical trials.
  • Fluid retention, weight gain and peripheral edema as a consequence of the androgenic-progestogenic activity.
  • Mood and CNS effects: mood changes, depression, headache and occasional hot flashes due to the hormonal suppression.

Contraindications · 7

  • Pregnancy and breastfeeding: absolute contraindication because the drug is teratogenic and can virilize fetal sexual development; reliable non-hormonal contraception is required in women of childbearing potential.
  • Severe hepatic dysfunction or active liver disease: contraindicated due to the hepatic burden from the 17alpha-ethynyl substitution.
  • High cardiovascular risk: contraindicated in cardiovascular disease, uncontrolled hypertension or a history of thromboembolism because of HDL reduction and fluid retention.
  • Severe renal dysfunction: fluid retention can worsen pre-existing kidney disease.
  • Competitive and elite sport: banned year-round by WADA (S1.1.a anabolic agent category), with metabolites detectable in urine for 7-14 days, so it must be absolutely avoided by athletes.
  • Hormone-sensitive tumors or undiagnosed abnormal genital bleeding: require evaluation before use given the hormonal activity.
  • Concurrent hormonal contraception: gestrinone can reduce its effectiveness, so concurrent use is not recommended.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Gestrinone (Dimetrose, Nemestran)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.